6-OAP abrogates the protective effects of IL-6 and IGF-I on myeloma cells through inhibition of Jak2/Stat3 and Akt signal pathways, respectively (Figure 5, A, B, D and E). This evidence concerns the gene STAT3 and plasma cell myeloma.